A population-based study in synchronous versus metachronous metastatic esophagogastric adenocarcinoma.
Marieke PapePauline A J VissersDavid BertwistleLaura McDonaldMarije SlingerlandNadia Haj MohammadLaurens V BeerepootJelle P RuurdaGrard A P NieuwenhuijzenPaul M JeeneHanneke W M van LaarhovenRob H A VerhoevenPublished in: Therapeutic advances in medical oncology (2022)
Patients with early metachronous metastatic disease have a worse survival compared with patients with synchronous or late metachronous metastatic disease. These patients less often receive systemic treatment, and even when treated, survival is worse compared with patients with synchronous or late metachronous metastatic disease, suggesting a more aggressive tumor behavior.